Coherus Oncology, Inc. (CHRS) Free cash flow 2016–2023
Coherus Oncology, Inc. (CHRS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$175.2MFY2023 · since FY2016: -$259.1M → -$175.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$175.2M | +28.0% |
| FY2022 | -$243.2M | -528.0% |
| FY2021 | -$38.7M | -126.4% |
| FY2020 | $146.9M | +453.7% |
| FY2019 | $26.5M | +116.6% |
| FY2018 | -$160.1M | +21.9% |
| FY2017 | -$204.9M | +20.9% |
| FY2016 | -$259.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice